<?xml version="1.0" encoding="UTF-8"?>
<p>Transchromosomic cattle have been developed to produce fully human polyclonal IgG antibodies following immunization (
 <xref rid="ref95" ref-type="bibr">Matsushita et al., 2014</xref>). Using this technology, polyclonal sera containing antibodies against the spike protein of MERS-CoV were produced (SAB-301) and demonstrated to be effective in neutralizing the virus 
 <italic>in vitro</italic> and reducing lung virus titers in infected mice (
 <xref rid="ref88" ref-type="bibr">Luke et al., 2016</xref>). A phase 1 randomized clinical trial aimed to evaluate the safety and tolerability of SAB-301 was conducted (NCT02788188). Results have been published and showed that the polyclonal human antibody is safe and well tolerated in patients at what could be considered therapeutic doses (
 <xref rid="ref15" ref-type="bibr">Beigel et al., 2018</xref>).
</p>
